Literature DB >> 16365723

Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation.

C Annaloro1, A Della Volpe, P Usardi, G Lambertenghi Deliliers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16365723     DOI： 10.1007/s10096-005-0065-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  11 in total

1.  Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations.

Authors:  Kristina Crothers; Charles B Beard; Joan Turner; Gena Groner; Melissa Fox; Alison Morris; Shary Eiser; Laurence Huang
Journal:  AIDS       Date:  2005-05-20       Impact factor: 4.177

2.  Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.

Authors:  T R Navin; C B Beard; L Huang; C del Rio; S Lee; N J Pieniazek; J L Carter; T Le; A Hightower; D Rimland
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

3.  Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis.

Authors:  Liang Ma; Joseph A Kovacs; Antonietta Cargnel; Antonella Valerio; Giovanna Fantoni; Chiara Atzori
Journal:  J Infect Dis       Date:  2002-04-30       Impact factor: 5.226

4.  The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia.

Authors:  M E van de Poll; M V Relling; E G Schuetz; P L Harrison; W Hughes; P M Flynn
Journal:  Cancer Chemother Pharmacol       Date:  2001-06       Impact factor: 3.333

5.  Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.

Authors:  P Kazanjian; W Armstrong; P A Hossler; W Burman; J Richardson; C H Lee; L Crane; J Katz; S R Meshnick
Journal:  J Infect Dis       Date:  2000-07-28       Impact factor: 5.226

Review 6.  Caspofungin: the first representative of a new antifungal class.

Authors:  Valérie Letscher-Bru; Raoul Herbrecht
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

7.  A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.

Authors:  C Colby; S McAfee; R Sackstein; D Finkelstein; J Fishman; T Spitzer
Journal:  Bone Marrow Transplant       Date:  1999-10       Impact factor: 5.483

8.  Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation.

Authors:  T K Marras; K Sanders; J H Lipton; H A Messner; J Conly; C K Chan
Journal:  Transpl Infect Dis       Date:  2002-06       Impact factor: 2.228

9.  Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii.

Authors:  M A Powles; P Liberator; J Anderson; Y Karkhanis; J F Dropinski; F A Bouffard; J M Balkovec; H Fujioka; M Aikawa; D McFadden; D Schmatz
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Caspofungin.

Authors:  Stanley C Deresinski; David A Stevens
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079
View more
  10 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

Review 2.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

3.  Efficacy of Trimethoprim-Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis.

Authors:  Hideo Kato; Mao Hagihara; Nobuhiro Asai; Takumi Umemura; Yuichi Shibata; Jun Hirai; Yuka Yamagishi; Takuya Iwamoto; Hiroshige Mikamo
Journal:  Antibiotics (Basel)       Date:  2022-05-26

4.  Echinocandins for Pneumocystis jirovecii pneumonia in non-HIV patients: A case report.

Authors:  Hui-Bin Huang; Jing-Min Peng; Bin Du
Journal:  Exp Ther Med       Date:  2018-08-07       Impact factor: 2.447

5.  Site-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to Caspofungin.

Authors:  A Luraschi; S Richard; P M Hauser
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

6.  Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions.

Authors:  Jose G Castro; Maya Morrison-Bryant
Journal:  HIV AIDS (Auckl)       Date:  2010-02-18

7.  Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: A case report and literature review.

Authors:  Di-Hong Yang; Yuan Xu; Lu Hong; Zhou-Ye Song; Wei-Hong Ge
Journal:  Respir Med Case Rep       Date:  2018-12-08

Review 8.  The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients.

Authors:  Ziyu Zhang; Qinhui Li; Xiaoyan Shen; Lankai Liao; Xia Wang; Min Song; Xi Zheng; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

9.  Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.

Authors:  Maria Luísa Lobo; Francisco Esteves; Bruno de Sousa; Fernando Cardoso; Melanie T Cushion; Francisco Antunes; Olga Matos
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  HIV-related Pneumocystis jirovecii pneumonia managed with caspofungin and veno-venous extracorporeal membrane oxygenation rescue therapy.

Authors:  Nathaniel Lee; David Lawrence; Brijesh Patel; Stephane Ledot
Journal:  BMJ Case Rep       Date:  2017-10-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.